section name header

Pronunciation

pra-soo-GREL

Classifications

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: thienopyridines

Indications

BEERS REMS


Action

  • Acts by irreversibly binding its active metabolite to the P2Y12 class of ADP receptors on platelets; inhibiting platelet activation and aggregation.
Therapeutic effects:
  • Decreased thrombotic events including cardiovascular death, nonfatal MI, and nonfatal stroke.

Pharmacokinetics

Absorption: Well absorbed following oral administration (79%), then rapidly converted to an active metabolite.

Distribution: Unknown.

Protein Binding: Active metabolite: 98%.

Metabolism/Excretion: Active metabolite is metabolized to two inactive compounds; 68% excreted in the urine and 27% in feces as inactive metabolites.

Half-Life: Active metabolite: 7 hr (range 2–15 hr).

Time/Action Profile

(effect on platelet function)

ROUTEONSETPEAKDURATION
POwithin 1 hr2 hr5–9 days



Following discontinuation.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Effient